SCM
WHWK

Suvretta Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Suvretta Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.8M Hold
3,700,000
– – 0.33% 46
2025
Q4 		$8.95M Hold
3,700,000
– – 0.18% 64
2025
Q3 		$7.03M Hold
3,700,000
– – 0.18% 64
2025
Q2 		$6.92M Hold
3,700,000
– – 0.21% 58
2025
Q1 		$6.59M Buy
+3,700,000
New +$9.66M 0.24% 60

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Suvretta Capital Management's WHWK Position: Q1 2026 in Review

Suvretta Capital Management held its Whitehawk Therapeutics (WHWK) position steady in Q1 2026 at 3,700,000 shares worth $12.8M. The position accounts for 0.33% of the portfolio, ranked #46.

Suvretta Capital Management first reported a position in WHWK in Q1 2025 and has held it in 5 quarters since. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Suvretta Capital Management held 3,700,000 shares of Whitehawk Therapeutics worth $12.8M as of Q1 2026.
  • Suvretta Capital Management left its Whitehawk Therapeutics share count unchanged in Q1 2026.
  • Whitehawk Therapeutics made up 0.33% of Suvretta Capital Management's portfolio in Q1 2026, its #46 holding.
  • Suvretta Capital Management first reported a position in Whitehawk Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.